General Information of the Protein
| Protein ID |
PT01126
|
||||
|---|---|---|---|---|---|
| Protein Name |
Aurora kinase C
|
||||
| Secondarily Protein Name |
Aurora 3
Aurora/IPL1-related kinase 3
Aurora/IPL1/Eg2 protein 2
Serine/threonine-protein kinase 13
Serine/threonine-protein kinase aurora-C
|
||||
| Gene Name |
AURKC
|
||||
| Secondarily Gene Name |
AIE2
AIK3
AIRK3
ARK3
STK13
|
||||
| Sequence |
MSSPRAVVQLGKAQPAGEELATANQTAQQPSSPAMRRLTVDDFEIGRPLGKGKFGNVYLARLKESHFIVALKVLFKSQIEKEGLEHQLRREIEIQAHLQHPNILRLYNYFHDARRVYLILEYAPRGELYKELQKSEKLDEQRTATIIEELADALTYCHDKKVIHRDIKPENLLLGFRGEVKIADFGWSVHTPSLRRKTMCGTLDYLPPEMIEGRTYDEKVDLWCIGVLCYELLVGYPPFESASHSETYRRILKVDVRFPLSMPLGARDLISRLLRYQPLERLPLAQILKHPWVQAHSRRVLPPCAQMAS
Show/Hide
|
||||
| Organism |
Homo sapiens, Human
|
||||
| Protein Classification |
Enzyme
>
Kinase
>
Protein Kinase
>
Other protein kinase group
>
Other protein kinase AUR family
|
||||
| Function |
Serine/threonine-protein kinase component of the chromosomal passenger complex (CPC), a complex that acts as a key regulator of mitosis. The CPC complex has essential functions at the centromere in ensuring correct chromosome alignment and segregation and is required for chromatin-induced microtubule stabilization and spindle assembly. Also plays a role in meiosis and more particularly in spermatogenesis. Has redundant cellular functions with AURKB and can rescue an AURKB knockdown. Like AURKB, AURKC phosphorylates histone H3 at 'Ser-10' and 'Ser-28'. AURKC phosphorylates the CPC complex subunits BIRC5/survivin and INCENP leading to increased AURKC activity. Phosphorylates TACC1, another protein involved in cell division, at 'Ser-228'.
Show/Hide
|
||||
| Uniprot ID |
Show/Hide
|
||||
| Ensembl ID | |||||
| HGNC ID | |||||
| Subcellular Location |
Nucleus
Chromosome
Chromosome
Centromere
Cytoplasm
Cytoskeleton
Spindle
|
||||
Clinical Information about the Protein
Target 1 ( Aurora kinase C (AURKC) )
| Target Type | Clinical trial Target | ||||
|---|---|---|---|---|---|
| Disease | 4 Target-related Diseases | 4 | |||
| 1 | Haematological malignancy [ICD-11: 2B33.Y] | ||||
| 2 | Prostate cancer [ICD-11: 2C82.0] | ||||
| 3 | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | ||||
| 4 | Advanced solid tumour [ICD-11: 2A00-2F9Z] | ||||
| Clinical Trial Drug(s) | 5 Clinical Trial Drugs | 5 | |||
| 1 | ABT-348 | Phase 2 | |||
| 2 | PHA-739358 | Phase 2 | |||
| 3 | AMG 900 | Phase 1 | |||
| 4 | GSK1070916 | Phase 1 | |||
| 5 | SNS-314 | Phase 1 | |||
| Discontinued Drug(s) | 1 Discontinued Drug | 1 | |||
| 1 | MK-6592 | Discontinued in Phase 1 | |||